Immunogenicity and Safety Study of NBP615 in Healthy Female

Summary

This was a randomized, double-blind, active-controlled, phase I/II clinical trial to enroll 200 healthy female including 80 healthy adult aged 19 to 26 years and 120 adolescents aged 9 to 13 years.

Timeline

Start

2018-12-22

Primary completion

2019-12-30

Completion

2019-12-30

Drugs

Indications